MiniMed (MMED) Q4 2026 earnings review
Top-Line Surges on CGM Strength, But Heavy Losses Persist
MiniMed delivered a record finish to FY26, breaking the $3B annual revenue mark with Q4 sales growing 15.6% to $837M. Growth was overwhelmingly driven by international CGM adoption. However, the top-line acceleration failed to translate to the bottom line. Net loss widened to $183M (EPS of -$0.68), weighed down by a massive $168M unclassified 'other operating expense' and an unusually high tax provision. While the FDA clearance of MiniMed Flex and FY27 organic growth guidance of ~10% project confidence, the complete lack of operating leverage remains a glaring issue for investors.
🐂 Bull Case
CGM revenue skyrocketed 21.6% YoY in Q4, driving the worldwide CGM attachment rate to 68%. The ecosystem is stickier and generating robust recurring revenue.
FDA clearance for MiniMed Flex and MiniMed Go, alongside the global launch of the 780G with Instinct sensor, positions FY27 for a major hardware upgrade cycle.
🐻 Bear Case
Despite a 15.6% revenue jump, net loss actually worsened YoY to $183M. Operating expenses remain severely bloated, preventing any meaningful path to GAAP profitability.
U.S. sales grew a meager 1.5%, and global pump sales reversed, falling 5.5%. The company is heavily reliant on the upcoming Flex launch to revive its domestic hardware business.
⚖️ Verdict: ⚪
Neutral. The pipeline delivery and international CGM growth are undeniably impressive. However, the reversing pump segment and opaque, nine-figure operating expenses make the quality of earnings exceptionally poor.
Key Themes
The Bottom-Line Black Box
Despite a $75M YoY increase in Gross Profit for Q4, the company's operating loss remained severe at $91M. This was driven by a sudden $168M 'Other operating expense' that perfectly replaced last year's $165M litigation charge. Furthermore, a bizarre $93M income tax provision was booked against a pre-tax loss of $90M. This lack of expense transparency severely contradicts the management narrative of a 'strong finish.'
U.S. Market and Pump Sales Reversing
While total revenue grew rapidly, the core hardware business is contracting. Global pump revenue fell 5.5% YoY to $146M, and total U.S. revenue grew a decelerating 1.5%. Management claims this is a temporary demand shift as customers wait for the newly cleared MiniMed Flex. If this pent-up demand doesn't materialize immediately in Q1 FY27, it signals deeper competitive market share losses.
International CGM Growth is the Engine
International sales grew an accelerating 22.4% as reported (12.2% organic), fueled heavily by the Simplera capacity expansion. Continuous Glucose Monitoring (CGM) is now the company's powerhouse, up 21.6% YoY to $420M in Q4, representing 50% of total company revenue. This shift towards high-margin recurring consumables is structurally improving gross margins.
Aggressive Product Pipeline Execution
MiniMed is advancing its pipeline faster than expected. The U.S. FDA clearance of the MiniMed Flex next-gen pump and the MiniMed Go Smart MDI system unlocks the domestic market. Simultaneously, securing the CE Mark for the 780G with Instinct ensures international momentum will remain stable into FY27.
Favorable Foreign Exchange Tailwinds (Macro)
A significant portion of the international growth story was driven by macro currency fluctuations. Of the $110M YoY increase in Q4 International net sales, nearly half ($50M) was a pure currency benefit. While organic growth of 12.2% is still robust, investors should be aware that the reported 22.4% international growth rate overstates the true volume momentum.
Other KPIs
Accelerating from 55.9% in Q4 FY25. Despite the heavy net losses, unit economics are improving. Gross profit rose to $480M on $837M in sales, reflecting the favorable mix shift toward the fast-growing CGM segment and efficient scaling of international operations.
Stable YoY for the full year, though Q4 saw a 7.4% sequential increase. The flat annual volume highlights that top-line growth is currently being driven by higher attachment rates (now 68%, up 700 bps YoY) and price/mix rather than an expanding core hardware user base.
Guidance
Accelerating compared to FY26's organic growth of 8.0%. Management is banking on the launches of MiniMed Flex and MiniMed Go to reaccelerate the U.S. market. Note that this target includes a 1.0% to 1.5% artificial benefit from an extra week in the fiscal calendar.
Management is introducing an Adjusted EBITDA target to steer focus away from deep GAAP net losses. Achieving 16% will require severe operating expense discipline, particularly reigning in the SG&A and opaque 'other operating expenses' that plagued FY26.
Key Questions
Transparency on Q4 Expenses
What exactly drove the $168M 'Other operating expense' in Q4, and is any portion of this expected to recur in FY27 as you target a 16% Adjusted EBITDA margin?
Tax Provision Anomalies
Can you explain the mechanics behind booking a $93M income tax provision against a pre-tax loss of $90M in Q4, and how should we model the effective tax rate going forward?
U.S. Hardware Reacceleration
With U.S. pump sales intentionally delayed by customers waiting for MiniMed Flex, how quickly do you expect this pent-up demand to translate into sequential volume growth in Q1 and Q2?